rs104894141 — CYP17A1 W17X

CYP17A1 W17X — A Premature Stop That Halts Steroid Synthesis at the First Step

The human body's ability to make cortisol, estrogens, and androgens all runs through a single enzymatic checkpoint: CYP17A1, or cytochrome P450 17α-hydroxylase/17,20-lyase¹¹ CYP17A1, or cytochrome P450 17α-hydroxylase/17,20-lyase
A bifunctional enzyme in the adrenal cortex and gonads that performs two sequential reactions essential for cortisol and sex steroid biosynthesis. Losing either activity disrupts the entire hormonal cascade downstream. The rs104894141 variant introduces a premature stop codon at the very beginning of this protein — position 17 out of 508 amino acids — leaving the cell with essentially no functional enzyme at all. The result, when two defective alleles are inherited, is 17α-hydroxylase deficiency (17OHD)²² 17α-hydroxylase deficiency (17OHD)
Also called congenital adrenal hyperplasia due to CYP17A1 deficiency, OMIM #202110. A rare autosomal recessive disorder accounting for ~1% of CAH cases, with an estimated incidence of approximately 1 in 50,000 births: the distinctive syndrome of hypertension, low potassium, and absent pubertal development.

The W17X variant was first documented in a Japanese patient³³ documented in a Japanese patient
Suzuki et al., J Clin Endocrinol Metab, 1998. The patient had a 46,XY karyotype, completely female external genitalia, absent pubertal development, and hypertension — the classic presentation of complete combined 17α-hydroxylase/17,20-lyase deficiency with a 46,XY karyotype presenting with female external genitalia, absent pubertal development, and hypertension. The variant was found in compound heterozygosity with a second mutation (IVS2+5G→T, a splice-donor disruption). This pattern — compound heterozygosity with two distinct CYP17A1 loss-of-function alleles — is the most common genetic architecture for clinical 17OHD.

The Mechanism

CYP17A1 performs two consecutive reactions in steroid biosynthesis. First, 17α-hydroxylation⁴⁴ 17α-hydroxylation
Converts pregnenolone → 17α-hydroxypregnenolone and progesterone → 17α-hydroxyprogesterone; these are the required precursors for cortisol production in the adrenal cortex's zona fasciculata. Second, 17,20-lyase activity⁵⁵ 17,20-lyase activity
Cleaves the C17–C20 bond, generating DHEA and androstenedione — the entry points into the sex steroid synthesis pathway for both estrogens and androgens in gonads and adrenals.

The W17X mutation (c.51G>A on the coding strand, plus-strand C>T at chr10:102837311) creates a stop codon at amino acid position 17 — just 16 residues into the protein, before any of the functional domains (heme-binding, substrate-binding, electron transfer) are even assembled. The resulting truncated peptide is non-functional and almost certainly degraded by nonsense-mediated mRNA decay. With no CYP17A1 activity, steroidogenesis is entirely shunted away from cortisol and sex steroids. Pregnenolone and progesterone accumulate and are instead converted to deoxycorticosterone (DOC)⁶⁶ deoxycorticosterone (DOC)
A potent mineralocorticoid — the second most active naturally occurring mineralocorticoid after aldosterone. DOC excess causes sodium retention, fluid overload, hypertension, hypokalemia, and suppressed renin and aldosterone through the zona glomerulosa pathway. Low cortisol drives ACTH up, which amplifies DOC production further. The gonads, meanwhile, cannot produce testosterone or estradiol — causing complete sexual infantilism regardless of chromosomal sex.

The Evidence

A large meta-analysis of 465 patients⁷⁷ meta-analysis of 465 patients
Willemsen et al., J Clin Endocrinol Metab, 2025 — 178 case reports and cohort studies from 1988–2022 documents the natural history of 17OHD in detail. Hypertension was present in 57% of patients at diagnosis, hypokalemia in 45%, primary amenorrhea in 38%, and disordered sexual development in 59.5%. Mean age at diagnosis was 19.0 years. Phenotypic sex was female in 90.8% despite chromosomal sex being XY in 52.5% of the cohort — reflecting the complete feminization of XY individuals when sex steroid synthesis is absent.

The broad phenotypic spectrum⁸⁸ broad phenotypic spectrum
Sun et al., Eur J Endocrinol, 2021 — 8 patients with 17OHD, including two with unexpectedly preserved cortisol synthesis despite absent sex steroids of 17OHD has been increasingly recognized. Null/null genotypes (two stop codons or frameshift mutations, like W17X compound heterozygous) consistently produce the complete phenotype. Urinary steroid metabolite profiling by mass spectrometry effectively predicts disease severity and can guide diagnosis before genetic results are available.

One important diagnostic pitfall: the mineralocorticoid-excess pattern (hypertension, hypokalemia, suppressed renin, elevated DOC) closely mimics primary aldosteronism⁹⁹ primary aldosteronism
Akkus, Endocr Metab Immune Disord Drug Targets, 2023 — two 17OHD patients misdiagnosed as primary aldosteronism until adrenal imaging, gonadotropin levels, and genetic testing revealed the correct diagnosis. The distinguishing feature is hypogonadism: primary aldosteronism does not cause absent puberty or sexual infantilism.

Practical Actions

For homozygous or compound heterozygous individuals (TT or, in compound het patients, CT with another loss-of-function allele on the opposite chromosome), the diagnosis of 17OHD requires lifelong hormonal management: glucocorticoid replacement to suppress ACTH (and thereby DOC excess), sex hormone replacement to induce and maintain secondary sexual characteristics, and monitoring of blood pressure and potassium.

For heterozygous carriers (CT), no clinical syndrome results — one functional allele is sufficient for adequate steroidogenesis. Carrier status is relevant for reproductive planning: two carriers have a 25% chance of producing an affected child.

Interactions

The W17X variant acts as a complete loss-of-function allele. Its clinical expression depends on the second allele: compound heterozygosity with any other CYP17A1 null allele (frameshift, stop, splice-disrupting) produces the complete 17OHD phenotype identical to W17X homozygosity. Compound heterozygosity with a partial loss-of-function missense allele can produce partial 17OHD, with residual enzyme activity and a milder, often female-predominant presentation (recurrent ovarian cysts, oligomenorrhea, partial breast development in 46,XX individuals; variable phenotypes in 46,XY).

Other CYP17A1 pathogenic variants in the GeneOps database — including rs104894135 (Ser106Pro), rs104894137, rs104894138, and rs104894143 — cause the same enzyme deficiency through different molecular mechanisms. The disease phenotype when any two loss-of-function CYP17A1 alleles are combined is clinically equivalent regardless of which specific variants are involved.